| Name | Title | Contact Details |
|---|---|---|
Jace Stoker |
Associate Director of Procurement and | Profile |
Janelle Gordon |
VP of People Operations | Profile |
Daniel Benavides |
Director, Talent Acquisition Operations | Profile |
Lina Nilsson |
Vice President of Product | Profile |
Lindsay Foot Ellinger |
Sr. Director of Procurement | Profile |
io is a biotechnology company that focuses on improving the quality of protein and overall nutrition through advanced Ingredient Optimized technology. They improve powders and supplements used in food production, transforming the performance of protein...
Chemrx is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.
Greater Nashua Mental Health believes in empowering people to lead full and satisfying lives through effective treatment and support.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.